Publications by authors named "Peter Bousquet"

Claim this Profile
N
NRF2 activator A-1396076 ameliorates inflammation in autoimmune disease models by inhibiting antigen dependent T cell activation.
Christian Goess, Sonia Terrillon, Martha Mayo, Peter Bousquet, Craig Wallace

J Transl Autoimmun· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats.
Christopher M Harris, Scott Mittelstadt, Patricia Banfor, Peter Bousquet, David B Duignan

J Pharmacol Exp Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
Bradford L McRae, Alon D Levin, Manon E Wildenberg, Pim J Koelink, Peter Bousquet

J Crohns Colitis· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.
Adrian D Hobson, Christopher M Harris, Elizabeth L van der Kam, Sean C Turner, Ayome Abibi, Peter Bousquet

J Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways.
Chih-Liang Chin, Madhavi Pai, Peter F Bousquet, Annette J Schwartz, Elizabeth M O'Connor

J Neuroimmunol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Zhiqin Ji, Asma A Ahmed, Daniel H Albert, Jennifer J Bouska, Peter F Bousquet

J Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
Irini Akritopoulou-Zanze, Daniel H Albert, Peter F Bousquet, George A Cunha, Christopher M Harris

Bioorg Med Chem Lett· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Jürgen Dinges, Daniel H Albert, Lee D Arnold, Kimba L Ashworth, Irini Akritopoulou-Zanze, Peter F Bousquet

J Med Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Yujia Dai, Kresna Hartandi, Zhiqin Ji, Asma A Ahmed, Daniel H Albert, Peter F Bousquet

J Med Chem· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thienopyridine urea inhibitors of KDR kinase.
H Robin Heyman, Robin R Frey, Peter F Bousquet, George A Cunha, Maria D Moskey

Bioorg Med Chem Lett· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Zhiqin Ji, Asma A Ahmed, Daniel H Albert, Jennifer J Bouska, Peter F Bousquet

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors.
Jürgen Dinges, Irini Akritopoulou-Zanze, Lee D Arnold, Teresa Barlozzari, Peter F Bousquet

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.
Jürgen Dinges, Kimba L Ashworth, Irini Akritopoulou-Zanze, Lee D Arnold, Steven A Baumeister, Peter F Bousquet

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Daniel H Albert, Paul Tapang, Terrance J Magoc, Lori J Pease, David R Reuter, Peter F Bousquet

Mol Cancer Ther· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Yujia Dai, Yan Guo, Robin R Frey, Zhiqin Ji, Michael L Curtin, Peter F Bousquet

J Med Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isoindolinone ureas: a novel class of KDR kinase inhibitors.
Michael L Curtin, Robin R Frey, H Robin Heyman, Kathy A Sarris, Douglas H Steinman, Peter F Bousquet

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis